Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials

Madi, A., Fisher, D., Maughan, T. S., Colley, J. P., Meade, A. M., Maynard, J., Humphreys, V., Wasan, H., Adams, R. A. ORCID: https://orcid.org/0000-0003-3915-7243, Idziaszczyk, S., Harris, R., Kaplan, R. S. and Cheadle, J. P. ORCID: https://orcid.org/0000-0001-9453-8458 2018. Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials. Presented at: 43rd ESMO Congress 2018, Munich, Germany, 19-23 October 2018. Annals of Oncology. , vol.29 (Supple) Oxford University Press, VIII22. 10.1093/annonc/mdy269.072

Full text not available from this repository.

Abstract

Rare genetic variants in DPYP increase toxicity and screening for them prevents serious complications by upfront reduction in 5FU dose; however, most patients with severe toxicities do not have a rare mutation. We have previously shown that 2 common DPYD variants were associated with toxicity in patients with advanced colorectal cancer treated on COIN & COIN-B (abstract 3509, ASCO 2013): Cys29Arg [rs1801265] (Minor Allele Frequency (MAF) 0.21) and Val732Ile [rs1801160] (MAF 0.04). We have now genotyped 4 rare variants using the same cohort.

Item Type:	Conference or Workshop Item (Paper)
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Oxford University Press
ISSN:	0923-7534
Last Modified:	27 Nov 2022 13:22
URI:	https://orca.cardiff.ac.uk/id/eprint/138302

Actions (repository staff only)

Edit Item